Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q2 2023 Earnings Presentation
26 slides from Nanologica Ab's earnings presentation, Jul 7, 2023
Slide 1: Interim Report Q2 2023 Nanologica AB (publ)
INTERIM REPORT Q2 2023 NANOLOGICA AB (PUBL)
Slide 2: Period in Brief
PERIOD IN BRIEF FINANCIAL SUMMARY • Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) • The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) • Loss after tax for the quarter amounted
Slide 3: CEO Comment: One Milestone Passed – Now We Look Forward
CEO COMMENT ONE MILESTONE PASSED – NOW WE LOOK FORWARD During the quarter, we reached an important milestone when we were finally able to approve our product in chromatography – NLAB Saga® – and after that make the first delivery to a customer who will use it in their production of insulin. The fine
Slide 4: CEO Comment (continued)
By focusing on Chromatography, we create prerequisites for reaching positive cash flow faster. Cash flow from operating activities is expected to improve significantly already in the second half of 2023, as sales of products within preparative chromatography increase, and production costs already ha
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine through porous silica Nanologica is a Swedish nanotechnology company world-leading in developing nanoporous silica particles for purification by chromatography. A proprietary production method enables the company to create supreme products by precisely
Slide 6: Business Area Chromatography
BUSINESS AREA CHROMATOGRAPHY After fine-tuning one of the production steps, the In June, the company participated at CPhI in company's product in preparative Shanghai. This is "China's one-stop-shop for the chromatography, NLAB Saga®, has been pharmaceutical industry" with more than 3,000 approved a
Slide 7: Business Area Drug Development and Operating Income
BUSINESS AREA DRUG company at Nasdaq Main Market and write-down of obsolete inventories. DEVELOPMENT The work within Drug Development has reached Net financial items for the quarter amounted to a point where further development requires a lot TSEK -1,359 (-1,076), and for the half-year to of resourc
Slide 8: Fluctuations in Revenue Generation, External Factors
beginning of the year, mainly relating to dedicated percent at the beginning of the year. equipment for large-scale production of silica at the contract manufacturer Sterling Pharma Solutions. The book value of tangible fixed assets FLUCTUATIONS IN REVENUE amounted to TSEK 4,051 compared to TSEK GEN
Slide 9: Employees and Organization, Patents, Share Information
Climate change poses a major risk to humanity ticker NICA. As per June 30, 2023, the number of from a global perspective, with financial risks as a registered outstanding shares amounted to consequence. At present, however, Nanologica 36,146,142 and the registered share capital assesses that climate
Slide 10: Risks and Uncertainties, Auditors Review
are expected to increase and make up the as production risks, price changes on raw majority of Nanologica's revenue. The company materials and inputs, and currency fluctuations. A considers it reasonable to achieve sales in detailed description of risk exposure and risk preparative chromatography ex
Slide 11: Financial Reports and Notes
Si NZ GICA FINANCIAL REPORTS AND NOTES
Slide 12: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2023 2022 2023 2022 2022 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Net sales 672 210 1 026 479 1 555 Change in inventories, finished goods 569 21 853 -1 202 -1 276 Capitalized work for own use 960 1 113 2 362 1 518 4 272 Other operating income 16
Slide 13: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2023 2022 2022 Amounts in TSEK Jun 30 Jun 30 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 23 685 11 916 14 724 Concessions, patents, licenses, trademarks and similar rights 1 572 1 499 1 407 Tangible fi
Slide 14: Consolidated Statement of Changes in Equity and Cash Flow Statement
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2023 2022 2023 2022 2022 Amounts in TSEK Apr - Jun Apr - Jun Jan - Jun Jan - Jun Jan - Dec Total equity at the beginning of the period 61 064 35 681 73 158 51 596 51 596 Profit/loss for the year -14 671 -13 473 -26 764 -29 388 -55 231 Other comprehensive i
Slide 15: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 16: Segment Information
Segment information is provided only for the group. In the table below, the business area Chromatography is titled Chroma, and the business area Drug Development is titled DD. 2023 Apr - Jun Corp Amounts in TSEK Chroma DD Function Total Net sales 672 0 0 672 Raw materials, consumables and change in
Slide 17: Note 5 Distribution of Income, Note 6 Financial Assets at Fair Value
2022 Jan - Dec Corp Amounts in TSEK Chroma DD Function Total Net sales 1 555 0 0 1 555 Raw materials, consumables and change in inventories -2 528 -64 0 -2 592 Gross profit -973 -64 0 -1 037 Other operating items -22 683 -11 003 -16 126 -49 812 Operating profit/loss -23 656 -11 067 -16 126 -50 850 V
Slide 18: Financial Assets at Fair Value, Note 7 Inventories
Short-term financial investments Holdings in short-term financial investments are continuously measured at fair value with a change in value in profit or loss. Holdings in listed shares are continuously valued at fair value according to Level 1 of the valuation hierarchy. Listed holdings are valued
Slide 19: Note 9 Significant Events After the Period, Note 10 Definitions of Key Figures
Transactions during the second quarter • Costs regarding loans from Flerie Invest AB amounted to TSEK 1,411 during the quarter and relate to interest and commitment fee. Payments regarding loans amounted to TSEK 1,340 during the quarter. • Purchase of equipment from NorthX Biologics Matfors AB amoun
Slide 20: Derivation of Alternative Performance Measures
* Derivation of alternative performance measures * When the operating profit/loss is negative, no recalculation regarding dilution is made. Nanologica’s Interim Report Q2 2023 20
Slide 21: Group Quarterly Data
GROUP QUARTERLY DATA * Alternative performance measures that are not defined by IFRS. For definition, please see note 10. Nanologica’s Interim Report Q2 2023 21
Slide 22: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY STATEMENT OF COMREHENSIVE INCOME FOR THE PARENT COMPANY Nanologica’s Interim Report Q2 2023 22
Slide 23: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY Nanologica’s Interim Report Q2 2023 23
Slide 24: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY Nanologica’s Interim Report Q2 2023 24
Slide 25: Statement of Changes in Equity and Cash Flow Statement for the Parent Company
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY CASH FLOW STATEMENT FOR THE PARENT COMPANY Nanologica’s Interim Report Q2 2023 25
Slide 26: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G 151 36 Södertälje Tel: 08-410 749 49 www.nanologica.com